Jounce’s latest setback dampens outlook for another cancer immunotherapy target

An experimental cancer immunotherapy developed by biotechnology company Jounce Therapeutics didn’t help shrink lung cancer tumors in a Phase 2 trial, prompting the company Tuesday to cancel plans to advance it into late-stage testing.